Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.19 is in line with its 3-year average of -0.19, around the middle of its 3-year range (-0.60–0.19).
As of the fiscal period ended Tuesday, March 31, 2026. 53.87% above its 12-month average of -0.41.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2025 (2026-03-31): -0.19.
DEBT TO EQUITY RATIO
-0.19
DEBT TO EQUITY RATIO AVG TTM
-0.41
DEBT TO EQUITY RATIO AVG 3Y
-0.21
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+53.87%
CURRENT VS 3Y AVG
+8.04%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 564 covered companies
CURRENT VS SECTOR MEDIAN
-247.10%
vs the sector median at left
Market Cap
$63.30M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.03
Market Cap
$61.60M
Debt to Equity Ratio
N/A
TTM Avg
1.49
3Y Avg
1.10
5Y Avg
0.74
Market Cap
$65.00M
Debt to Equity Ratio
21.48
TTM Avg
9.81
3Y Avg
10.71
5Y Avg
5.89
Market Cap
$65.23M
Debt to Equity Ratio
N/A
TTM Avg
5.13
3Y Avg
7.62
5Y Avg
5.19
Market Cap
$59.51M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alps Group Inc (ALPS) | $63.23M | -0.19 | -0.41 | -0.21 | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.30M | 0.02 | 0.01 | 0.01 | 0.03 |
| InterCure Ltd. (INCR)vs › | $64.68M | 0.46 | 0.49 | 0.48 | 0.36 |
| PDS Biotechnology Corporation (PDSB)vs › | $61.60M | N/A | 1.49 | 1.10 | 0.74 |
| Heron Therapeutics, Inc. (HRTX)vs › | $65.00M | 21.48 | 9.81 | 10.71 | 5.89 |
| Gossamer Bio, Inc. (GOSS)vs › | $65.23M | N/A | 5.13 | 7.62 | 5.19 |
| Cingulate Inc. (CING)vs › | $65.73M | 0.27 | 2.09 | 1.90 | 1.47 |
| Adicet Bio, Inc. (ACET)vs › | $60.30M | 0.11 | 0.09 | 0.09 | 0.11 |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.51M | N/A | 0.00 | 0.00 | 0.00 |
| Fractyl Health, Inc. (GUTS)vs › | $59.23M | N/A | 4.36 | 4.36 | 3.25 |
Debt/Equity
-0.19
Current Ratio
0.36
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-03-31 | -0.19 |
| 2026-03-31 | -0.19 |
| 2025-09-30 | -0.53 |
| 2025-09-30 | -0.53 |
| 2025-06-30 | -0.47 |
| 2025-03-31 | -0.58 |
| 2024-12-31 | -0.60 |
| 2024-09-30 | 0.19 |
| 2024-06-30 | 0.17 |
| 2024-03-31 | 0.13 |
| 2023-12-31 | 0.08 |
| 2023-03-31 | 0.02 |
| 2022-12-31 | 0.00 |
